INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 58 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q1 2016. The put-call ratio across all filers is 0.65 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $0 | – | 75 | 0.0% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 75 | -99.3% | 0.00% | -100.0% |
| Q3 2017 | $15,000 | -40.0% | 10,120 | +11.0% | 0.00% | 0.0% |
| Q2 2017 | $25,000 | -24.2% | 9,120 | +12.3% | 0.00% | 0.0% |
| Q1 2017 | $33,000 | -2.9% | 8,120 | 0.0% | 0.00% | -50.0% |
| Q4 2016 | $34,000 | +277.8% | 8,120 | +515.2% | 0.00% | – |
| Q3 2016 | $9,000 | +12.5% | 1,320 | 0.0% | 0.00% | – |
| Q2 2016 | $8,000 | -55.6% | 1,320 | -47.1% | 0.00% | -100.0% |
| Q4 2015 | $18,000 | – | 2,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 246,966 | $1,778,000 | 2.19% |
| WELCH & FORBES LLC | 902,286 | $6,496,000 | 0.21% |
| Alambic Investment Management, L.P. | 25,100 | $181,000 | 0.11% |
| EMERSON INVESTMENT MANAGEMENT, LLC | 74,175 | $534,000 | 0.10% |
| Hayek Kallen Investment Management | 10,965 | $79,000 | 0.06% |
| Yellowstone Partners, LLC | 10,045 | $72,000 | 0.03% |
| Ausdal Financial Partners, Inc. | 7,750 | $56,000 | 0.03% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 29,647 | $213,000 | 0.03% |
| GROUP ONE TRADING, L.P. | 61,856 | $445,000 | 0.01% |
| Cambridge Investment Research Advisors, Inc. | 10,500 | $76,000 | 0.00% |